| Jon D Gabrielsen, MD | |
|
100 N Academy Ave, Danville, PA 17822-4903 | |
| (570) 271-6361 | |
| (570) 271-6578 |
| Full Name | Jon D Gabrielsen |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 26 Years |
| Location | 100 N Academy Ave, Danville, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093829939 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | MD431765 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Evangelical Community Hospital | Lewisburg, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Evangelical Medical Services Organization | 9133033087 | 229 |
News Archive
Thermo Fisher Scientific Inc. has announced the launch of its new triple quadrupole gas chromatography-mass spectrometry (GC-MS/MS) system designed to offer best-in-class selectivity, analytical performance and productivity. The Thermo Scientific TSQ Quantum XLS Ultra delivers the increased matrix selectivity needed for challenging applications that require lower levels of quantitation in extremely complex matrix extracts. With its exceptional sensitivity, easy detection and reliable peak integration, the system provides superior performance for the most difficult of matrix challenges.
A study involving more than 200,000 people worldwide has identified 29 DNA sequence variations in locations across the human genome that influence blood pressure.
Onyx Pharmaceuticals, Inc. today announced updated results from the Phase 2b 003-A1 study of single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma. Carfilzomib achieved a clinical benefit rate (CBR) (minimal response or greater) in the study population of 37 percent with a duration of response (DOR) of 8.3 months.
As previously disclosed, Albany Molecular Research, Inc. ("AMRI" or "the "Company") (NASDAQ: AMRI) received a warning letter, dated August 17, 2010, from the U.S. Food and Drug Administration (FDA) in connection with the FDA's inspection of the Company's pharmaceutical manufacturing facility located in Burlington, Massachusetts.
More than a year after becoming one of the first medical institutions nationally to complete a revolutionary gene replacement surgery to restore vision in patients with retinal degeneration, surgeons at the of The Vision Center at Children's Hospital Los Angeles have successfully completed the procedure on an additional 13 patients.
› Verified 6 days ago
| Entity Name | Geisinger Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366493868 PECOS PAC ID: 5395657001 Enrollment ID: O20040130000518 |
News Archive
Thermo Fisher Scientific Inc. has announced the launch of its new triple quadrupole gas chromatography-mass spectrometry (GC-MS/MS) system designed to offer best-in-class selectivity, analytical performance and productivity. The Thermo Scientific TSQ Quantum XLS Ultra delivers the increased matrix selectivity needed for challenging applications that require lower levels of quantitation in extremely complex matrix extracts. With its exceptional sensitivity, easy detection and reliable peak integration, the system provides superior performance for the most difficult of matrix challenges.
A study involving more than 200,000 people worldwide has identified 29 DNA sequence variations in locations across the human genome that influence blood pressure.
Onyx Pharmaceuticals, Inc. today announced updated results from the Phase 2b 003-A1 study of single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma. Carfilzomib achieved a clinical benefit rate (CBR) (minimal response or greater) in the study population of 37 percent with a duration of response (DOR) of 8.3 months.
As previously disclosed, Albany Molecular Research, Inc. ("AMRI" or "the "Company") (NASDAQ: AMRI) received a warning letter, dated August 17, 2010, from the U.S. Food and Drug Administration (FDA) in connection with the FDA's inspection of the Company's pharmaceutical manufacturing facility located in Burlington, Massachusetts.
More than a year after becoming one of the first medical institutions nationally to complete a revolutionary gene replacement surgery to restore vision in patients with retinal degeneration, surgeons at the of The Vision Center at Children's Hospital Los Angeles have successfully completed the procedure on an additional 13 patients.
› Verified 6 days ago
| Entity Name | Evangelical Medical Services Organization |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295834984 PECOS PAC ID: 9133033087 Enrollment ID: O20040310000212 |
News Archive
Thermo Fisher Scientific Inc. has announced the launch of its new triple quadrupole gas chromatography-mass spectrometry (GC-MS/MS) system designed to offer best-in-class selectivity, analytical performance and productivity. The Thermo Scientific TSQ Quantum XLS Ultra delivers the increased matrix selectivity needed for challenging applications that require lower levels of quantitation in extremely complex matrix extracts. With its exceptional sensitivity, easy detection and reliable peak integration, the system provides superior performance for the most difficult of matrix challenges.
A study involving more than 200,000 people worldwide has identified 29 DNA sequence variations in locations across the human genome that influence blood pressure.
Onyx Pharmaceuticals, Inc. today announced updated results from the Phase 2b 003-A1 study of single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma. Carfilzomib achieved a clinical benefit rate (CBR) (minimal response or greater) in the study population of 37 percent with a duration of response (DOR) of 8.3 months.
As previously disclosed, Albany Molecular Research, Inc. ("AMRI" or "the "Company") (NASDAQ: AMRI) received a warning letter, dated August 17, 2010, from the U.S. Food and Drug Administration (FDA) in connection with the FDA's inspection of the Company's pharmaceutical manufacturing facility located in Burlington, Massachusetts.
More than a year after becoming one of the first medical institutions nationally to complete a revolutionary gene replacement surgery to restore vision in patients with retinal degeneration, surgeons at the of The Vision Center at Children's Hospital Los Angeles have successfully completed the procedure on an additional 13 patients.
› Verified 6 days ago
| Entity Name | Geisinger-hm Joint Venture Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144876137 PECOS PAC ID: 1355676370 Enrollment ID: O20190826000803 |
News Archive
Thermo Fisher Scientific Inc. has announced the launch of its new triple quadrupole gas chromatography-mass spectrometry (GC-MS/MS) system designed to offer best-in-class selectivity, analytical performance and productivity. The Thermo Scientific TSQ Quantum XLS Ultra delivers the increased matrix selectivity needed for challenging applications that require lower levels of quantitation in extremely complex matrix extracts. With its exceptional sensitivity, easy detection and reliable peak integration, the system provides superior performance for the most difficult of matrix challenges.
A study involving more than 200,000 people worldwide has identified 29 DNA sequence variations in locations across the human genome that influence blood pressure.
Onyx Pharmaceuticals, Inc. today announced updated results from the Phase 2b 003-A1 study of single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma. Carfilzomib achieved a clinical benefit rate (CBR) (minimal response or greater) in the study population of 37 percent with a duration of response (DOR) of 8.3 months.
As previously disclosed, Albany Molecular Research, Inc. ("AMRI" or "the "Company") (NASDAQ: AMRI) received a warning letter, dated August 17, 2010, from the U.S. Food and Drug Administration (FDA) in connection with the FDA's inspection of the Company's pharmaceutical manufacturing facility located in Burlington, Massachusetts.
More than a year after becoming one of the first medical institutions nationally to complete a revolutionary gene replacement surgery to restore vision in patients with retinal degeneration, surgeons at the of The Vision Center at Children's Hospital Los Angeles have successfully completed the procedure on an additional 13 patients.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jon D Gabrielsen, MD 100 N Academy Ave, Danville, PA 17822-4903 Ph: (570) 271-6144 | Jon D Gabrielsen, MD 100 N Academy Ave, Danville, PA 17822-4903 Ph: (570) 271-6361 |
News Archive
Thermo Fisher Scientific Inc. has announced the launch of its new triple quadrupole gas chromatography-mass spectrometry (GC-MS/MS) system designed to offer best-in-class selectivity, analytical performance and productivity. The Thermo Scientific TSQ Quantum XLS Ultra delivers the increased matrix selectivity needed for challenging applications that require lower levels of quantitation in extremely complex matrix extracts. With its exceptional sensitivity, easy detection and reliable peak integration, the system provides superior performance for the most difficult of matrix challenges.
A study involving more than 200,000 people worldwide has identified 29 DNA sequence variations in locations across the human genome that influence blood pressure.
Onyx Pharmaceuticals, Inc. today announced updated results from the Phase 2b 003-A1 study of single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma. Carfilzomib achieved a clinical benefit rate (CBR) (minimal response or greater) in the study population of 37 percent with a duration of response (DOR) of 8.3 months.
As previously disclosed, Albany Molecular Research, Inc. ("AMRI" or "the "Company") (NASDAQ: AMRI) received a warning letter, dated August 17, 2010, from the U.S. Food and Drug Administration (FDA) in connection with the FDA's inspection of the Company's pharmaceutical manufacturing facility located in Burlington, Massachusetts.
More than a year after becoming one of the first medical institutions nationally to complete a revolutionary gene replacement surgery to restore vision in patients with retinal degeneration, surgeons at the of The Vision Center at Children's Hospital Los Angeles have successfully completed the procedure on an additional 13 patients.
› Verified 6 days ago
Dr. Tara Jean Loux, MD Surgery Medicare: Medicare Enrolled Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-214-7967 | |
Christie Buonpane, Surgery Medicare: Medicare Enrolled Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6211 | |
Gabriel Mekel Nakhal, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6361 | |
Alexandra Maningat, Surgery Medicare: Not Enrolled in Medicare Practice Location: 100 N Academy Ave # Mc27-70, Danville, PA 17822 Phone: 570-214-2403 | |
Anthony John Georges, M.D. Surgery Medicare: Medicare Enrolled Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-214-7967 | |
Mr. Luiz Goncalves Foernges, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6211 |